Thrombosis
Conference Coverage
Andexanet alfa effectively reverses factor Xa inhibition
HONOLULU – The drug establishes good or excellent hemostasis in 82% of patients with acute major bleeding associated...
Commentary
A new era of TTP treatment
Many questions remain following the FDA’s approval of caplacizumab, specifically, which patients should receive it. The high cost of the drug is...
Conference Coverage
Repeat VTE risk heightened in HIV patients
SEATTLE – Two studies detail the risk factors of first-time venous thromboembolism and heightened incidence of repeat VTE in patients with HIV.
From the Journals
Coagulation pathway may play role in IBD
Increased activity of a gene associated with the coagulation pathway is linked to more severe inflammatory bowel disease and treatment nonresponse...
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
News from the FDA/CDC
FDA: Safety signal emerged with higher dose of tofacitinib in RA study
The FDA is working with Pfizer to better understand how the signal affects patients and how the drug should be used, the agency said in a...
From the Journals
ICYMI: Rivaroxaban reduces VTE incidence in ambulatory cancer patients
However, the reduction lost significance if treatment with rivaroxaban was halted.
From the Journals
Supplementary compression doesn’t improve DVT odds in critically ill
SAN DIEGO – The procedure carries few risks, aside from patient discomfort.
From the Journals
ICYMI: Andexanet alfa reduces anti–factor Xa activity from apixaban, rivaroxaban
Reductions were similar for those receiving apixaban and rivaroxaban.
From the Journals
Venous thromboembolism risk elevated in ankylosing spondylitis patients
AS patients showed a significantly increased risk of VTE, compared with controls, especially during the first year after diagnosis.
Conference Coverage
Biomarkers predict VTE risk with menopausal oral hormone therapy
CHICAGO – Pretreatment high D-dimer spells 500% increased VTE risk on oral hormone therapy.